AlphaYou
Overview
Smart money at a glance
Filings to Oct 12, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 1 cutMore adding
Market overview
Fundamentals Jul 21- 52-wk high
- $32.56
- 52-wk low
- $19.05
- Mkt cap
- $3.85B
- P/E
- 18.2x
- Fwd P/E
- 12.9x
- Beta
- 0.74
- P/S
- 6.5x
- P/B
- 3.8x
- Profit margin
- +37.1%
- Op margin
- +49.0%
- ROE
- +24.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CPRX filings
Are insiders buying or selling Catalyst Pharmaceuticals Inc (CPRX) stock?
Neither. Catalyst Pharmaceuticals Inc (CPRX) insiders filed no open-market purchases or sales in the 90 days to Oct 12, 2026, according to SEC Form 4 filings.
Which members of Congress have traded CPRX recently?
None. No member of Congress disclosed a CPRX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CPRX smart-money data?
This summary uses filings available on Oct 12, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (2)
- QR
Qube Research
$60.6M
added
- MW
Marshall Wace
$23.7M
added
Sells/Trims (1)
- BO
Bank of America
$34.0M
trimmed
How top traders are positioned
No tracked top-trader positions in CPRX right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No earnings history.
What the street expects next
Financials
Is the business strong?
Fairly priced and profitable.
- Net margin
- 37.1%
- P/E
- 18.20
- Forward P/E
- 12.95
- Market cap
- $3.9B
Valuation
- P/S6.46
- P/B3.81
Quality
- Operating margin49.0%
- ROE24.5%
- ROA16.3%
Growth
- Beta0.74
Technicals
Price structure
Market data unavailable.